Baxter International (BAX) Could Be 9% Undervalued Following Its Recent Rebound

Baxter International (BAX) has drawn fresh attention as investors reassess its recent share performance and fundamentals. The stock shows mixed longer term returns along with modest annual revenue growth and a sharp rebound in net income.

Recent trading has tilted in Baxter International's favor, with a 30 day share price return of 10.88% and a year to date gain of 29.64%. The 1 year total shareholder return of 9.51% still sits against a 5 year total shareholder loss of 65.73%, so momentum is rebuilding from a low base.

Scan Baxter International alongside other healthcare names showing rebuilding momentum with our curated list of solid balance sheet and fundamentals (25 results) as a starting universe for further research.

Baxter International has bounced hard in a short span, yet longer term holders still sit on deep losses. Does the current valuation still skew the risk reward toward fresh buyers, or has most of the easy upside already reset?

Most Popular Narrative: 9% Undervalued

Baxter International is priced at $25.28 against a widely followed fair value estimate of about $27.92, so the narrative implies some remaining upside if that gap eventually closes.

The main factor that needs to go right is that Baxter International translates its decentralization, Baxter GPS program, and balance sheet deleveraging into sustained cash generation without a relapse in hospital consumables or infusion related headwinds.

See why 19 investors see Baxter International as 9% undervalued.

Result: Fair Value of $27.92 (UNDERVALUED)

Still, the Baxter International story carries real execution risk if issues with the Novum IQ pump drag on or if constraints in injectables supply continue to pressure pharmaceutical earnings.

Find out about the key risks to this Baxter International narrative.

Next Steps

Mixed messages in the Baxter International story can make the signal feel muddled. Move quickly, review the underlying data, and decide where you stand with 3 key rewards and 1 important warning sign.

Looking for more Baxter International sized investment ideas?

If Baxter International has you rethinking your watchlist, do not stop here. Broaden your opportunity set and pressure test your thesis against other compelling setups.

• Target potential bargains by scanning companies that combine quality fundamentals with room for rerating using our 33 high quality undervalued stocks.
• Build a cash flow focused portfolio by reviewing income payers with resilient profiles through the 8 dividend fortresses.
• Dial down portfolio stress by concentrating on financially robust businesses surfaced in the 32 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com